Second-generation tau PET radioligands [18F]PI-2620 and [18F]PM-PPB3 (also known as [18F]APN-1607, or florzolotau) have been studied in patients with AD [17,18] and PSP [19,20]. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.